Download PDFPDF
856 Routine baseline blood tests predicting pembrolizumab sensitivity in advanced high-grade serous ovarian cancer (AHGSOC) 1st line therapy: substudy from the NEOPEMBROV/GINECO (NCT03275506) randomized trial
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address